GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma

Growth factor receptor-bound protein 7 (GRB7) gene is located adjacent to the HER2 gene on the 17q12-21 amplicon, is often coamplified with HER2 in a subset of breast cancers, and has been implicated in resistance to anti-HER2 and antiestrogen therapy. This study investigated the correlation of GRB7 expression by immunohistochemistry with HER2 expression, HER2 amplification, increased chromosome 17 copy number, and other prognostic and predictive factors in invasive breast cancer, including histologic grade, pathologic stage, and ER, PR, and p53 status. Paraffin-embedded samples of 188 invasive breast carcinomas with documented HER2, ER, and PR testing were collected and divided into 3 groups: cases positive for HER2 overexpression/gene amplification (n=60), negative for HER2 overexpression (n=97), and cases with increased chromosome 17 copy number without HER2 amplification (n=31). GRB7 expression was evaluated on all 188 cases. In addition, p53 immunohistochemistry was performed on 13 HER2+/GRB7+ cases and 39 HER2+/GRB7− cases. GRB7 expression correlated strongly with HER2 overexpression. GRB7 expression was present in 20/60 (33.33%) of HER2+ cases, compared with 1/97 (1.03%) HER2− cases, and 1/31 (3.22%) increased chromosome 17 copy number cases (P<0.0001). In HER2+ cases, GRB7 expression was found to correlate significantly with a greater degree of HER2 amplification. The mean±SEM HER2 copy number was 21.14±2.59 in GRB7+ cases, compared with 9.8±1.38 in GRB7− cases (P=0.0001). GRB7 expression correlated significantly with ER negativity (P=0.012) and p53 positivity (P=0.03). GRB7 expression did not correlate with histologic grade, pathologic stage, or PR expression. Our data shows that GRB7 expression in invasive breast cancer correlates with markers of a more aggressive phenotype, including HER2 overexpression, a greater degree of HER2 amplification, ER negativity, and p53 positivity.

[1]  S. Luoh,et al.  GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. , 2007, Carcinogenesis.

[2]  S. Luoh,et al.  GRB7 protein over-expression and clinical outcome in breast cancer , 2011, Breast Cancer Research and Treatment.

[3]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[4]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[5]  Gajendra P. S. Raghava,et al.  Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients , 2014, Scientific Reports.

[6]  S. Gunn,et al.  Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event , 2009, Modern Pathology.

[7]  S. Petroni,et al.  Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer? , 2012, Archives of pathology & laboratory medicine.

[8]  J. Silverman,et al.  Correlation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[9]  J. Guan,et al.  The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions , 2001, Oncogene.

[10]  J. Silverman,et al.  Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma , 2009, Modern Pathology.

[11]  A. Børresen-Dale,et al.  The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells , 2013, Molecular oncology.

[12]  Y. Kluger,et al.  Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  D. Krag,et al.  Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells , 2007, British Journal of Cancer.

[14]  John S McMurray,et al.  Targeting SH2 domains in breast cancer. , 2014, Future medicinal chemistry.

[15]  I. Bièche,et al.  Prognostic value of ERBB family mRNA expression in breast carcinomas , 2003, International journal of cancer.

[16]  A. Luini,et al.  HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. , 2007, European journal of cancer.

[17]  Pierre-Marie Martin,et al.  Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers , 2011, Breast Cancer Research.

[18]  A. Ashworth,et al.  Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis , 2009, The Journal of pathology.

[19]  Daniel Birnbaum,et al.  Genome profiling of ERBB2-amplified breast cancers , 2010, BMC Cancer.

[20]  S. Naber,et al.  Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. , 1990, American journal of clinical pathology.

[21]  K. Semba,et al.  Expression screening of 17q12–21 amplicon reveals GRB7 as an ERBB2‐dependent oncogene , 2012, FEBS letters.

[22]  M. Gunzburg,et al.  The Discovery of Phenylbenzamide Derivatives as Grb7‐Based Antitumor Agents , 2013, ChemMedChem.

[23]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[24]  R. Gray,et al.  Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer , 2011, Clinical Cancer Research.

[25]  A. Villalobo,et al.  Genomic Organization and Control of the Grb7 Gene Family , 2008, Current genomics.

[26]  Päivikki Kauraniemi,et al.  Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. , 2003, The American journal of pathology.

[27]  B. Leyland-Jones,et al.  Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules. , 2013, American journal of cancer research.

[28]  T. Grogan,et al.  The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study , 2005, The American journal of surgical pathology.

[29]  D. Krag,et al.  Grb7-based molecular therapeutics in cancer , 2003, Expert Reviews in Molecular Medicine.

[30]  P. Diest,et al.  Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification , 2010, Breast Cancer Research and Treatment.

[31]  M. Ringnér,et al.  High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer , 2010, Breast Cancer Research.

[32]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. D’Eustachio,et al.  The SH2 domain protein GRB‐7 is co‐amplified, overexpressed and in a tight complex with HER2 in breast cancer. , 1994, The EMBO journal.

[34]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[35]  O. Monni,et al.  New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. , 2001, Cancer research.

[36]  Mario Passalacqua,et al.  Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression , 2010, PloS one.

[37]  P. Neven,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2012, The New England journal of medicine.

[38]  Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer. , 2012, Oncology reports.

[39]  D. Krag,et al.  GRB7 is required for triple-negative breast cancer cell invasion and survival , 2012, Breast Cancer Research and Treatment.

[40]  C. Heldin,et al.  Grb7 is a Downstream Signaling Component of Platelet-derived Growth Factor α- and β-Receptors* , 1996, The Journal of Biological Chemistry.

[41]  P. Kauraniemi,et al.  Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. , 2006, Endocrine-related cancer.

[42]  J. Bartlett,et al.  Chromosome 17 Aneusomy is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma , 2004, Breast Cancer Research and Treatment.